Literature DB >> 18511800

Risk assessment and lipid modification for primary and secondary prevention of cardiovascular disease: summary of NICE guidance.

Angela Cooper1, Norma O'Flynn.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18511800      PMCID: PMC2405875          DOI: 10.1136/bmj.39554.624086.AD

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  2 in total

1.  Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease.

Authors:  J Robson
Journal:  Heart       Date:  2008-08-13       Impact factor: 5.994

2.  Cardiovascular disease risk profiles.

Authors:  K M Anderson; P M Odell; P W Wilson; W B Kannel
Journal:  Am Heart J       Date:  1991-01       Impact factor: 4.749

  2 in total
  25 in total

1.  Cardiovascular risk tables.

Authors:  Thierry Christiaens
Journal:  BMJ       Date:  2008-06-23

2.  NICE on lipid modification: NICE has overestimated cardiovascular risk.

Authors:  Richard G Richards
Journal:  BMJ       Date:  2008-06-14

Review 3.  Big Data and Health Economics: Strengths, Weaknesses, Opportunities and Threats.

Authors:  Brendan Collins
Journal:  Pharmacoeconomics       Date:  2016-02       Impact factor: 4.981

Review 4.  Non-alcoholic fatty liver disease: what has changed in the treatment since the beginning?

Authors:  Bülent Baran; Filiz Akyüz
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

5.  The case for more intensive use of statins.

Authors:  Jordan Fulcher; Anthony Keech
Journal:  Ther Adv Chronic Dis       Date:  2012-09       Impact factor: 5.091

Review 6.  Cardiovascular risk.

Authors:  Rupert A Payne
Journal:  Br J Clin Pharmacol       Date:  2012-09       Impact factor: 4.335

Review 7.  Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.

Authors:  Richard Kones
Journal:  Drug Des Devel Ther       Date:  2011-06-13       Impact factor: 4.162

Review 8.  Esophageal cancer: The latest on chemoprevention and state of the art therapies.

Authors:  Gregoire F Le Bras; Muhammad H Farooq; Gary W Falk; Claudia D Andl
Journal:  Pharmacol Res       Date:  2016-08-24       Impact factor: 7.658

9.  An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study.

Authors:  Gary S Collins; Douglas G Altman
Journal:  BMJ       Date:  2010-05-13

10.  An independent external validation and evaluation of QRISK cardiovascular risk prediction: a prospective open cohort study.

Authors:  Gary S Collins; Douglas G Altman
Journal:  BMJ       Date:  2009-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.